Table of Contents
What is the difference between fosaprepitant and aprepitant?
Fosaprepitant is a prodrug of aprepitant, and it is converted to aprepitant within 30 minutes when administered intravenously.
How much does fosaprepitant cost?
Fosaprepitant is a cost-effective antiemetic medication when compared to the three-day oral aprepitant antiemetic regimen, which costs about $705 (Lexicomp, 2016a). The single dose of fosaprepitant costs about $320 (Lexicomp, 2016b).
What is the use of fosaprepitant?
Aprepitant injection and fosaprepitant injection are used along with other medications to prevent nausea and vomiting in adults that may occur within 24 hours or several days after receiving certain cancer chemotherapy treatments. Fosaprepitant injection can also be used in children 6 months of age and older.
Is fosaprepitant the same as Emend?
Fosaprepitant (Ivemend®, Merck) is a new intravenous prodrug formulation of the oral neurokinin-1 (NK1) receptor antagonist aprepitant (Emend®, Merck).
What is another name for fosaprepitant?
Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant.
How often can you give fosaprepitant?
Adults: 150 mg on Day 1. Pediatrics (6 months to 17 years): a single-day of EMEND for injection on Day 1 (for single dose chemotherapy regimens) or a 3- day EMEND regimen of EMEND for injection on Day 1 and EMEND capsules or oral suspension on Days 2 and 3 (for single or multi-day chemotherapy regimens).
Is fosaprepitant chemotherapy?
Fosaprepitant is a prodrug of aprepitant, a neurokinin1 (NK1) receptor antagonist used in prophylactic antiemetic regimens used prior to cytotoxic chemotherapy. Fosaprepitant is being developed to provide a parenterally administered alternative to the orally administered aprepitant.
Is fosaprepitant FDA approved?
FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy (MEC) treatment of established nausea and vomiting.
Does fosaprepitant prolong QT?
The lack of QTc increase at this high dose of fosaprepitant and resulting aprepitant plasma exposures support the expectation that clinical doses of fosaprepitant or aprepitant will not be associated with significant QTc prolongation.